Phospho-DNM1L (Ser637) Antibody

Basic Research Questions

• What is DNM1L/DRP1 and why is phosphorylation at Ser637 significant?

DNM1L (Dynamin-1-like protein), commonly known as DRP1, functions primarily in mitochondrial and peroxisomal division. It mediates membrane fission through oligomerization into membrane-associated tubular structures that wrap around scission sites to constrict and sever mitochondrial membranes through a GTP hydrolysis-dependent mechanism . The protein's recruitment to mitochondrial membranes is facilitated by receptor proteins including MFF, MIEF1, and MIEF2 .

Phosphorylation at Ser637 (human numbering) is particularly significant because it serves as a key regulatory switch for DRP1 activity. When phosphorylated at this site by protein kinase A (PKA) and calcium/calmodulin-dependent protein kinase (CAMK1), DRP1's GTPase activity is inhibited, resulting in decreased mitochondrial fission and promoting mitochondrial elongation . Conversely, dephosphorylation at this site by calcineurin (PPP3CA) promotes mitochondrial fission by enhancing DRP1's GTPase activity .

• What are the primary applications of Phospho-DNM1L (Ser637) antibodies in scientific research?

Phospho-DNM1L (Ser637) antibodies serve as valuable tools across multiple research applications:

These antibodies are particularly valuable for studying mitochondrial dynamics, neurodegenerative diseases, cancer biology, and metabolic disorders where alterations in mitochondrial fission and fusion play crucial roles in pathogenesis .

• How does the phosphorylation state of DRP1 correlate with clinical outcomes in disease contexts?

Research has demonstrated that DRP1 phosphorylation status can serve as a prognostic indicator in certain pathological conditions. A study on nasopharyngeal carcinoma (NPC) revealed:

Additionally, p-DRP1 (Ser616) levels showed significant association with advanced clinical stage (TNM > 2, P = 0.0002), whereas p-DRP1 (Ser637) did not correlate with clinical stage . These findings suggest that the balance between phosphorylation at these two sites plays a critical role in cancer progression, potentially through effects on mitochondrial dynamics, energy metabolism, and apoptotic resistance.

• What experimental challenges exist when detecting phosphorylated DRP1 across different species?

Species variation presents significant challenges for researchers working with phospho-DRP1 antibodies:

These variations necessitate thoughtful antibody selection and validation strategies:

• Confirm epitope conservation through sequence alignment before selecting antibodies

• Use antibodies specifically validated for the target species

• Employ positive controls derived from the species being studied

• Consider phosphatase treatment as a negative control

• Use phospho-specific peptide competition assays to confirm specificity

When reporting research findings, it is essential to clearly specify which species-specific phosphorylation site is being examined to prevent confusion in the literature.

• What are the recommended storage and handling conditions for Phospho-DNM1L (Ser637) antibodies?

Proper storage and handling are critical for maintaining antibody functionality:

Best practices include:

• Aliquoting upon receipt to minimize freeze-thaw cycles

• Storing in buffer containing stabilizers (typically 50% glycerol, 0.5% BSA, and 0.02% sodium azide)

• Spinning the vial before opening to collect solution at the bottom

• Gently mixing the antibody solution before use

• Avoiding storage in frost-free freezers which undergo cyclical temperature changes

Following these guidelines helps maintain antibody specificity and sensitivity throughout the research project timeline.

Advanced Research Questions

• What control samples are essential for validating the specificity of Phospho-DNM1L (Ser637) antibodies?

Robust validation requires thoughtfully designed control samples:

Quality control testing reported by manufacturers typically includes peptide inhibition assays showing that target band detection is prevented by pre-blocking with the immunogen phosphopeptide but not with the corresponding non-phosphopeptide . Affinity binding assays may also be used to quantify binding affinity (e.g., KD of 1.3 x 10-6) .

• How can forskolin treatment be optimized for generating positive control samples?

Forskolin provides a reliable method for generating positive control samples when working with Phospho-DNM1L (Ser637) antibodies:

Mechanism: Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels and subsequently activating protein kinase A (PKA), which phosphorylates DRP1 at Ser637.

Optimized Protocol:

• Cell Treatment:

  • Culture cells to 70-80% confluency

  • Treat with 50 mM forskolin dissolved in DMSO

  • Include vehicle control (DMSO at equivalent concentration)

  • Incubate for 30-60 minutes at 37°C, 5% CO2

• Sample Processing:

  • Harvest cells in ice-cold lysis buffer containing phosphatase inhibitors

  • Standardize protein concentration across samples

  • Perform SDS-PAGE and Western blot using standard protocols

  • Probe with anti-phospho-DRP1 (Ser637) antibody at recommended dilution

  • Strip and reprobe with anti-total DRP1 antibody

• Analysis:

  • Calculate p-DRP1/total DRP1 ratio

  • Compare forskolin-treated vs. control samples

This approach has been validated in quality control testing of commercial antibodies like the ZooMAb® clone 5G23, which successfully detected p-DRP1-Ser637 in forskolin-treated NIH3T3 cell lysates .

• How do different phosphorylation sites on DRP1 interact to regulate mitochondrial dynamics?

DRP1 function is regulated by a complex interplay of phosphorylation at multiple sites:

These modifications create a phosphorylation-based molecular switch:

• During conditions requiring increased mitochondrial fusion (e.g., nutrient starvation), PKA phosphorylates Ser637, inhibiting fission

• During mitosis or situations requiring increased mitochondrial fission, CDK1 phosphorylates Ser616, promoting fission

The balance between these phosphorylation events is crucial for mitochondrial health. In pathological contexts, this balance can be disrupted:

• In nasopharyngeal carcinoma, increased p-DRP1 (Ser616) and decreased p-DRP1 (Ser637) correlate with poorer prognosis

• In neurodegenerative diseases, alterations in this phosphorylation balance may contribute to mitochondrial dysfunction

When designing experiments to study these interactions, it's essential to examine both phosphorylation sites simultaneously and calculate phosphorylated/total DRP1 ratios to understand the functional implications.

• What methodological approaches can overcome technical challenges in detecting phosphorylated DRP1 in complex samples?

Detecting phosphorylated DRP1 in complex samples presents several challenges requiring specialized methodological approaches:

Challenge: Low Abundance of Phosphorylated Protein

• Solution: Immunoprecipitate total DRP1 first, then probe with phospho-specific antibody

• Alternative: Use phospho-protein enrichment techniques before Western blotting

Challenge: Phosphatase Activity During Sample Processing

• Solution: Use comprehensive phosphatase inhibitor cocktails containing both serine/threonine and tyrosine phosphatase inhibitors

• Protocol: Add inhibitors immediately upon cell lysis and maintain samples at 4°C throughout processing

Challenge: Cross-Reactivity With Related Proteins

• Solution: Validate antibody specificity using recombinant phosphorylated and non-phosphorylated DRP1

• Control: Include peptide competition assays with phosphorylated and non-phosphorylated peptides

Challenge: Detecting Changes in Phosphorylation State

• Solution: Always normalize phospho-DRP1 signal to total DRP1 levels

• Analysis: Calculate and report p-DRP1/total DRP1 ratio rather than absolute phospho-signal

Challenge: Tissue-Specific Variation

• Solution: Optimize extraction protocols for specific tissue types

• Consideration: Brain tissue may require different extraction methods than cultured cells or other organs

These methodological refinements significantly improve the reliability and reproducibility of phosphorylated DRP1 detection across experimental systems.

• How can Phospho-DNM1L (Ser637) antibodies be utilized in investigating mitochondrial dynamics in neurodegenerative diseases?

Phospho-DNM1L (Ser637) antibodies offer valuable insights into mitochondrial dynamics in neurodegenerative contexts:

Experimental Applications:

• Comparative Analysis of Disease vs. Control Tissues:

  • Quantify p-DRP1 (Ser637)/total DRP1 ratios in affected brain regions

  • Correlate with measures of mitochondrial morphology and function

  • Example finding: Altered phosphorylation patterns correlate with decreased apoptosis rates in glaucoma models

• Drug Screening Platforms:

  • Identify compounds that modulate DRP1 phosphorylation status

  • Monitor downstream effects on mitochondrial network integrity

  • Assess neuroprotective potential in cellular and animal models

• Therapeutic Antibody Development:

  • Target DNM1L with antibody-based approaches as demonstrated in glaucoma research

  • Monitor changes in phosphorylation state as a biomarker of treatment efficacy

  • Correlate with functional outcomes in animal models

• Pathway Analysis:

  • Investigate protein interactions with DNM1L using proteomic approaches

  • Research has identified three key protein clusters interacting with DNM1L:

    • Vesicle traffic-associated (NSF, SNCA, ARF1)

    • Mitochondrion-associated (HSP9A, SLC25A5/ANT2, GLUD1)

    • Cytoskeleton-associated (MAP1A) signaling pathways

These applications offer mechanistic insights into how disrupted mitochondrial dynamics contribute to neurodegeneration and highlight potential therapeutic strategies targeting DRP1 phosphorylation.